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128Objective: Intractable cyanosis after partial or complete cavopulmonary connection may rarely be managed by
creating a systemic arteriovenous fistula. We investigated the long-term performance of arteriovenous fistulae.
Methods:All 21 patients who received an arteriovenous fistula at The Hospital for Sick Children since the 1950s
were investigated using parametric competing risk techniques. Primary arteriovenous fistula indication was (1)
suboptimal pulmonary blood flow (N ¼ 15) or (2) pulmonary shunting via pulmonary arteriovenous malforma-
tions (N ¼ 6). Arteriovenous fistula longevity was determined by time to ‘‘occlusion’’ (absence of arteriovenous
fistula flow via surgical ligation or spontaneous occlusion).
Results:All 21 patients had previously undergone second-stage palliation (Glenn shunt¼ 13; bidirectional shunt
¼ 9). Five patients had undergone Fontan completion. Death in the presence of a functioning arteriovenous fistula
occurred in 5 patients. Patients with bidirectional shunts had a significantly higher risk of death with a functioning
arteriovenous fistula in situ (P ¼ .04). High hemoglobin concentrations were associated with best outcome, and
levels less than 170 g/L were associated with a high risk of death despite a functioning arteriovenous fistula (P<
.01). Arteriovenous fistula occlusion occurred in 10 patients. Earlier occlusion was associated with previous Fon-
tan completion (P¼ .02) and pulmonary arteriovenous malformations (P¼ .03). Surgical ligation during cardiac
transplantation was the cause of occlusion in 7 patients. In these 7 patients, the arteriovenous fistula functioned for
a median of 4.8 years. After transplantation, survival was 67%  19% at 5 years. Overall survival was 73% 
10% 15 years after receiving an arteriovenous fistula (longest survival, 27.3 years).
Conclusion: In patients with adequate hematocrit, arteriovenous fistula offers an effective bridge to transplanta-
tion when a high-risk Fontan procedure is deferred. Performance is best after unidirectional cavopulmonary con-
nection and worse in the presence of pulmonary arteriovenous malformations. Survival is 75% at 15 years,
despite being considered end stage. (J Thorac Cardiovasc Surg 2010;139:128-34)Supplemental material is available online.Intractable cyanosis after partial or complete cavopulmonary
connection may rarely be managed by creating a systemic
arteriovenous fistula (AVF). The logic behind this strategy
is to improve systemic oxygenation by augmenting cavopul-
monary shunt flow.1 However, the long-term consequences
of this end-stage palliative approach are not known.
Progressive cyanosis after cavopulmonary connection in-
cludes 2 distinct mechanisms. In the first situation, total cav-
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The Journal of Thoracic and Cardiovascular Surgsluggish pulmonary perfusion and poor oxygenation.1,2
The process may be exacerbated by poor ventricular perfor-
mance. The aim of AVF in this scenario is to augment total
pulmonary flow by increasing the superior vena caval pres-
sure within the cavopulmonary shunt.
In the second situation, intrapulmonary arteriovenous
malformations develop as a consequence of cavopulmonary
shunt physiology and the interruption of hepatopulmonary
blood flow.3,4 Right-to-left shunting within the lung then
leads to impaired oxygenation and systemic cyanosis. In
this scenario, creating an AVF to augment pulmonary perfu-
sion aims to compensate for the proportion of pulmonary
blood flow shunted through pulmonary arteriovenous mal-
formations. In addition, reestablishing first-pass pulmonary
metabolism of hepatic effluent may restore beneficial pulmo-
nary microvascular effects of a putative ‘‘hepatic factor.’’5
We investigatedour institutional experiencewith the use of
AVF as a method of palliating failing cavopulmonary shunts.
In particular, we aimed to (1) determine long-term outcomes
for AVF recipients, (2) investigate patient-specific features
associated with AVF performance, and (3) determine
whether the underlying indication for AVF contributes to
its long-term function.ery c January 2010
Abbreviation and Acronym
AVF ¼ arteriovenous fistula
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All 21 patients who underwent surgical creation of an AVF at The Hos-
pital for Sick Children between 1978 and 2007 were included in this retro-
spective investigation. To our knowledge, these include all such cases since
the introduction of open cardiac surgical procedures at The Hospital for Sick
Children in the late 1950s. Institutional ethics board approval was obtained,
but a waiver of consent was issued because of the retrospective nature and
because patients were not contacted directly.
The operative technique has been described.2 Briefly, under general an-
esthesia an incision is made 1 cm below and parallel to the lateral half of the
clavicle. The pectoralis major muscle is split, and the axillary neurovascular
bundle is identified. After systemic heparinization, a side-to-side anastomo-
sis (6–7 mm in length) is constructed between the axillary artery and vein.
The distal axillary vein is then ligated to yield a functional side-to-end arte-
riovenous anastomosis. Postoperative anticoagulation is not given.
The primary clinical indication for AVF creation was classified as 1) cy-
anosis due to pulmonary shunting via arteriovenous malformations or 2) cy-
anosis in the absence of arteriovenous malformations, presumed due to
inadequate overall cavopulmonary shunt flow and oxygenation. Pulmonary
arteriovenous malformations were confirmed preoperatively by angiogra-
phy.3 In the pre-Fontan era, AVF was pursued because the only alternative
was transplantation. Otherwise, the decision to undertake AVF was consid-
ered because the Fontan procedure had failed or subsequent Fontan comple-
tion or cardiac transplantation was considered an excessive risk for the
patient.
A functioning AVFwas defined as being patent (including at the point of
death). Therefore, its therapeutic longevity, or durability, is represented by
the duration of its patency: from the point of creation until the time of its
occlusion. The mechanism of occlusion may be spontaneous occlusion or
surgical division/ligation. Follow-up review of patients’ records was under-
taken in 2007 (mean of 11 years from the point of AVF, up to a maximum of
27.3 years). Procedural and clinical information was extracted and entered
into a database for analysis. Time-related outcomes were modeled using
multiphase hazard domain techniques.6 AVF longevity involved analyzing
the time to ‘‘AVF occlusion’’ (point of surgical division/ligation or known
spontaneous occlusion). Competing risks methodology7 was used to ac-
count for patients who died with a functioning AVF and were therefore
no longer at risk of AVF occlusion. Separate time-related hazard functions
are combined to yield the proportion of children reaching the defined tran-
sitional states at any given point in time. Parametric models were then sub-
jected to univariate risk-hazard analysis to identify patient-specific features
that influence the risk of (1) AVF occlusion, (2) death with a functioning
AVF in situ, and (3) all-cause mortality. Missing values were imputed
with the mean for that variable, and the number of missing values is given.
Descriptive statistics are presented as frequency with percentage of non-
missing values or median with range. Preoperative and postoperative com-
parisons of continuous variables were made using paired t tests. All analyses
were undertaken using SAS statistical software (SAS Institute Inc, Cary,
NC).RESULTS
The cohort characteristics are shown in Table 1. The pa-
tients were evenly distributed throughout the decades cov-
ered by this review (Figure E1). Tricuspid atresia (N ¼ 8)
was the most common primary diagnosis. At the time of
AVF creation, all patients had previously undergone pallia-The Journal of Thoracic and Cative cavopulmonary shunt (Glenn shunt, N ¼ 13; bidirec-
tional cavopulmonary connection, N ¼ 8), and 5 of these
had also undergone total cavopulmonary connection (Fon-
tan completion). AVFs were predominantly right-sided
(86%) and created at a median age of 13.5 years. The clin-
ical indication for AVF was confirmed pulmonary arteriove-
nous malformations in 6 patients or otherwise inadequate
pulmonary flow and oxygenation in 15 patients. The latter
group was a heterogenous case-mix including patients
with gradual cyanosis after Glenn in the pre-Fontan era or
otherwise specific problems, such as impaired left ventricu-
lar function, branch pulmonary artery stenoses interstitial
lung disease, and thrombosed great veins (Table E1).
AVFs resulted in a significant improvement in arterial ox-
ygen saturation at all postoperative time points compared
with pre-AVF values (Table 1). In addition, last documented
New York Heart Association symptom classification (irre-
spective of subsequent surgical management) was signifi-
cantly improved compared with pre-AVF values (Table 1).
Outcome of Arteriovenous Fistula
The time-related fate of the AVF was explored by exam-
ining the potential competing outcomes. For all patients,
the AVF may continue to function (N ¼ 6) or ‘‘occlude’’
(N ¼ 10; no longer provide arteriovenous shunting because
of surgical division/ligation or spontaneous thrombosis), or
otherwise the patient dies with a functioning AVF (N ¼ 5).
The competing outcomes of these end states for the AVF in
the study cohort are shown in Figure 1. Fifteen years after
receiving an AVF, 30%  11% of the study cohort
remained alive with a functioning AVF. In an additional
46%  11% of the study cohort, the AVF was occluded
but the patients remained alive, whereas 24%  10% of
patients died with a functioning conduit in situ.
Death With a Functioning Arteriovenous Fistula
Five patients died with a functioning AVF in situ. The
type of partial cavopulmonary influenced the risk of death
with a functioning AVF. Previous bidirectional cavopulmo-
nary shunt (vs unidirectional Glenn shunt) was associated
with a significantly higher time-related risk of death with
a functioning AVF in situ, even once adjusted for surgical
era (Table 2, Figure 2). The superior survival with a unidirec-
tional Glenn anastomosis was regardless of whether subse-
quent Fontan had been completed before receiving the
AVF (Table 2). In addition, whether the AVF was created
after second-stage palliation (cavopulmonary shunt) or Fon-
tan completion did not influence the time-related risk of
death with a functioning AVF in situ (P ¼ .89).
An important determinant of patient survival with a func-
tioningAVFwas the hemoglobin concentration at the time of
AVF creation. Lower hemoglobin levels were associated
with significantly worse survival (Figure 3, A) (P< .01).
The relationship between hemoglobin concentration andrdiovascular Surgery c Volume 139, Number 1 129
TABLE 1. Patient characteristics of the study cohort (N ¼ 21) of all
children at The Hospital for Sick Children who received an arteriovenous
fistula for end-stage cyanotic congenital heart disease
Characteristic
Missing
values
Frequency
or median % or range
Male 0 10 47
Operative age 0 13.5 5 mo to 36 y
Left AVF (vs right) 9 2 17
Diagnosis:
Tricuspid atresia 0 8 38
Pulmonary atresia 0 3 14
Atrioventricular canal defect 0 3 14
Double-outlet right ventricle 0 2 10
Double-inlet left ventricle 0 2 10
Hypoplastic left heart
syndrome
0 2 10
Transposition of the great
arteries
0 1 5
Previous CPS:
Glenn CPS 0 13 62
Bidirectional CPS 0 8 38
Previous Fontan palliation 0 5 24
Preoperative SaO2 (%) 11 74 63–90
Postoperative SaO2 in
operating room (%)
14 88* 80–95
Postoperative SaO2 at
discharge (%)
13 81* 75–95
Postoperative SaO2 at latest
follow-up (%)
12 83* 75–90
Preoperative hemoglobin (g/L) 11 172 110–233
Postoperative hemoglobin (g/L) 12 174 139–227
Preoperative NYHA class (g/L)
I 12 0 0
II 12 3 33
III 12 6 66
IV 12 0 0
Postoperative NYHA classy
I 11 5 50
II 11 2 20
III 11 3 30
IV 11 0 0
AVF, Arteriovenous fistula; CPS, cavopulmonary shunt; SaO2, arterial oxygen satura-
tion; NYHA, New York Heart Association classification. *P< .01 vs preoperative
value. yP ¼ .04 vs preoperative value.
FIGURE 1. Time-related transition to the mutually exclusive competing
end states of (1) AVF occlusion, (2) death with a functioning AVF in situ
or otherwise, or (3) alive with a functioning AVF in situ. At time zero, all
100% patients are alive with a functioning AVF. Thereafter, patients as-
sume one of the competing end states at variable rates. Fifteen years after
receiving an AVF, 44% 10% of patients remain alive with a functioning
AVF, 24% 8% of patients have died with a functioning AVF in situ, and
32%  11% of patients had an occluded AVF. The numbers at risk from
AVF occlusion were 11, 9, and 3 at 10, 15, and 20 years, respectively. Lines
represent the parametric determination of continuous point estimates. AVF,
Arteriovenous fistula.
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g/L were associated with particularly bad survival (Figure 3,
B). By contrast, the estimated 10-year risk of death with
a functioning AVFwas estimated to be 10% or less if the he-
moglobin concentration was more than 185 g/L at the time of
creating the AVF.Arteriovenous Fistula Longevity: Time to Occlusion
The AVF occluded in 10 patients and was ligated during
cardiac transplantation in 7 of these patients; alternatively it
was removed (N ¼ 1) or spontaneously occluded (N ¼ 1).
Risk factors associated with reduced functional longevity130 The Journal of Thoracic and Cardiovascular Surgof the AVF are shown in Table 2. The clinical indication for
AVF was a particularly important determinant of outcome.
AVFs created for a primary clinical indication of inadequate
pulmonary blood flow functioned significantly longer than
those created for a primary clinical indication of pulmonary
shunting via pulmonary arteriovenous malformations (param-
eter estimate,1.39; P ¼ .03). If the AVF was created for an
indication of arteriovenous malformations, less than 10%
would be predicted to be alive with a functioning AVF in
situ 15 years later (Figure 4, A). By contrast, if the AVF was
created because of inadequate pulmonary blood flow, approx-
imately 40% are estimated to be alive with a functioningAVF
in situ 15 years later (Figure 4, B).
Longevity of AVF function was significantly worse if the
AVF was created after Fontan completion versus after sec-
ond-stage palliation (parameter estimate, þ1.43; P ¼ .02,
Figure 5). If the AVF was created after Fontan completion,
less than 10%would be predicted to be alive with a function-
ing AVF in situ 15 years later (Figure 5, A). By contrast, if
the AVF was created after second-stage palliation, approxi-
mately 40% are predicted to be alive with a functioning
AVF in situ 15 years later (Figure 5, B).
The use of a Glenn unidirectional cavopulmonary shunt
also seemed to offer improved longevity of AVF function
(Table 2). Those who received an AVF after Glenn cavopul-
monary anastomosis (but before Fontan completion) had
significantly better freedom from AVF occlusion (P ¼
.03), although this effect was partly neutralized when
changes in surgical era were adjusted for. Neither systemicery c January 2010
TABLE 2. Univariate associations between patient-specific features and time-related risk of deathwith a functioning arteriovenous fistula in situ or
occlusion of arteriovenous fistula
Death with functioning AVF N ¼ 5 Occlusion of AVF N ¼ 10
Variable Parameter estimate P value Parameter estimate P value
Male — .16 — .22
Operative age (y) — .33 — .60
Left AVF vs right AVF — .11 — .65
Tricuspid atresia vs other diagnosis — .74 — .51
Unidirectional Glenn CPS at time of AVF — .13 1.33 .03
Adjusted for era* P ¼ .09
Unidirectional Glenn CPS, irrespective of subsequent Fontan 1.89 .04 — .08
Adjusted for era* P ¼ .05
Previous Fontan completion — .89 þ1.43 .02
Preoperative arterial oxygen saturation (%) — .56 — .30
Postoperative arterial oxygen saturations, immediate (%) — .62 — .30
Postoperative arterial oxygen saturations at discharge (%) — .95 — .21
Preoperative hemoglobin (g/dL) 0.07 <.01 — .20
Indication: pulmonary blood flow vs pulmonary arteriovenous
malformations
— .87 1.39 .03
AVF, Arteriovenous fistula; CPS, cardiopulmonary support. The use of a unidirectional Glenn shunt seemed to confer a general protective influence against both death with
a functioning AVF and AVF occlusion. *Interaction terms were explored between the use of unidirectional Glenn cavopulmonary shunts and operative era because increased
use of Glenn shunts correlated with earlier operative era (correlation coefficient,0.61; P< .01).
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moglobin concentration influenced AVF longevity.
Late Outcomes
Outcomes after arteriovenous fistula occlusion. Occlu-
sion pertains to cessation of AVF perfusion, and therefore
the end of its palliative efficacy. However, a significant por-
tion of the patients in whom the AVF occluded continued to
survive. At the close of follow-up (mean, 11 years), 5 of the
9 patients in whom the AVF occluded were still alive. Ka-
plan–Meier survival estimate for these 9 patients was there-
fore 73%  17% at 5 years after the AVF occluded.
In 7 of the 9 patients, the AVF occluded when cardiac
transplantation was undertaken. The interval from when
the AVFwas created to the point of transplantationwas ame-
dian of 4.8 years (range, 4 months to 17 years). Thereafter,
survival for these 7 patients was 67%  19% at 5 years
from the point of transplantation. Therefore, the AVF acted
as a bridge by delaying transplantation approximately 5
years, after which survival was favorable.
Overall late survival. Overall survival for all 21 patients
was 73%  10%, 73%  10%, and 37%  16% at 10,
15, and 20 years, respectively, from the time of AVF crea-
tion (numbers at risk: 13, 6, and 3, respectively). On univar-
iate analysis, no features were identified that significantly
influenced overall survival in this cohort. The longest survi-
vor lived for 27.3 years after the AVF was created.
DISCUSSION
Three quarters of this cohort, who all received an AVF as
an end-stage attempt to palliate intractable cyanosis, survivedThe Journal of Thoracic and Cafor another 15 years. Although creating an AVF in these cir-
cumstances is only rarely considered in contemporary West-
ern practice, this study demonstrates that an AVF remains
a useful management option. Their performance was most
favorable after second-stage palliation, particularly where
cyanosis was caused by suboptimal cavopulmonary shunt
flow. In these children, AVF may defer the need for subse-
quent further surgery (by5 years), and the technique there-
fore represents a useful bridge to cardiac transplantation.
AVF performance was optimal when cyanosis was not
attributable to pulmonary arteriovenous malformations.
The reasons for this are obscure but may stem from the
fact that intraparenchymal shunting is not addressed by the
AVF, and therefore the underlying defect persists (and
may progress) after the AVF is created. Instead, in the ab-
sence of pulmonary arteriovenous malformations, cyanosis
is likely attributable to an overall inadequate pulmonary
blood flow (whether secondary to poor cardiac output, low
Qp/Qs, or branch pulmonary artery stenoses), and therefore
creating an AVF more directly addresses the problem by
augmenting pulmonary perfusion pressure to yield a sus-
tained improvement in lung perfusion and oxygenation.
By contrast, the presence of intrapulmonary shunting via
arteriovenous malformations is associated with poor per-
formance of AVF. The mechanisms of pulmonary arteriove-
nous malformations are not fully clarified. Pulmonary
arteriovenous malformations originally were attributed to
lower lobe perfusion deficits arising from nonpulsatile
flow of unidirectional Glenn shunts8 in a time-dependent
manner.9 However, other cavopulmonary anastomoses with
nonpulsatile flow are not associated with high risk ofrdiovascular Surgery c Volume 139, Number 1 131
FIGURE 2. Time-related competing outcomes after receiving an AVF,
stratified by having undergone Glenn cavopulmonary anastomosis (A) or
bidirectional cavopulmonary anastomosis (B). Glenn anastomosis confers
a significant protective effect against death with a functioning AVF in
situ (parameter estimate, 1.7; P ¼ .01). To adjust for era-dependent
changes in surgical practice, the interaction between Glenn anastomosis
and operative era was explored as a risk factor and was also significant (pa-
rameter estimate,0.06; P¼ .04). In those who received a Glenn anastomo-
sis, 18% 10%were predicted to have died with a functioningAVFwithin
15 years. By contrast, the risk of death with a functioning AVF was 63%
20% at 15 years if bidirectional cavopulmonary anastomosis had previously
been undertaken. Lines represent parametric determination of continuous
point estimates. AVF, Arteriovenous fistula.
FIGURE 3. A, Time-related risk of death with a functioning AVF in situ,
stratified by the circulating hemoglobin concentration at the time of AVF
creation. Lower hemoglobin concentrations were associated with signifi-
cantly worse survival (parameter estimate, 0.07; P< .01). B, Nomogram
showing the proportion of patients alive 10 years after receiving an AVF
across the spectrum of baseline preoperative hemoglobin concentrations.
The relationship was nonlinear: hemoglobin levels less than 170g/L con-
ferred disproportionately high mortality, whereas levels more than 185g/L
were associated with 10-year risk of death with a functioning AVF in situ
of less than 10% 8%. The median hemoglobin concentration in the study
cohort was 175g/L (range, 110–230g/L). Lines represent parametric deter-
mination of continuous point estimates. AVF,Arteriovenous fistula;Hb, he-
moglobin.
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native neuroendocrine hypotheses have gained recent interest.
Congenital lesions inwhich hepatoenteric effluent is excluded
from the pulmonary circulation are associatedwith pulmonary
arteriovenousmalformations,whichmay reverse once normal
anatomic drainage is restored.5 In addition, patients with infe-
rior vena cava interruption demonstrate resolution of pulmo-
nary arteriovenous malformations once hepatic drainage is
included in the cavopulmonary circulation.10,11 Both acute
and chronic liver failure in other settings are also known to132 The Journal of Thoracic and Cardiovascular Surgbe associatedwith pulmonary vascular abnormalities (hepato-
pulmonary syndrome12). Collectively, these findings strongly
implicate an absence of humoral ‘‘hepatic factors’’ in the path-
ogenesis of pulmonary arteriovenous malformations.13,14
Poorer performance of AVF in the presence of pulmonary
AVF may therefore relate to the fact that underlying neuro-
endocrine abnormalities persist. Therefore, although AVF
may temporarily improve systemic oxygenation, progres-
sion of pulmonary shunting may continue unabated; how-
ever, AVF has been reported to initiate regression of
pulmonary arteriovenous malformations by McElhinney
and colleagues.15 The authors note that first-pass pulmonary
metabolism of hepatic drainage seems to be a necessaryery c January 2010
FIGURE 4. Time-related competing outcomes after receiving an AVF,
stratified by whether the primary indication was intrapulmonary shunting
via arteriovenous malformations (A) or inadequate pulmonary blood flow
(B). The rate of AVF occlusion was significantly higher in patients in
whom the indication was pulmonary arteriovenous malformations (param-
eter estimate,1.6; P ¼ .01). The proportion of AVFs that had occluded at
15 years was 76% 18% (pulmonary arteriovenous malformations) versus
29% 12% (inadequate pulmonary blood flow). Lines represent paramet-
ric determination of continuous point estimates. AVF,Arteriovenous fistula.
FIGURE 5. Time-related competing outcomes after receiving an AVF,
stratified by AVF created after Fontan completion (A) or AVF created after
second-stage palliation (B). The rate of AVF occlusion was significantly
higher in patients in whom Fontan completion had already been undertaken
at the time of AVF creation (parameter estimate,þ1.59; P ¼ .01). The pro-
portion of AVFs that had occluded at 15 years was 76% 17% (AVF after
Fontan) versus 29% 11% (AVF after second-stage palliation). Lines rep-
resent parametric determination of continuous point estimates. AVF, Arte-
riovenous fistula.
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teriovenous malformations. They postulate that the AVF
provides a route for hepatic drainage ejected from the single
ventricle to bypass systemic capillary beds and instead per-
fuse the lung on first-pass, via the cavopulmonary shunt. The
interesting concept of a hepatopulmonary neuroendocrine
axis may be important in the fetal circulation. Cavopulmo-
nary connection resembles a partial return toward fetal circu-
lation, and pulmonary arteriovenous malformations have
been demonstrated in fetal sheep.16
An important finding of this investigation is that AVF
performance with unidirectional (classic Glenn) cavopul-
monary shunts outperformed those with either bidirectional
partial cavopulmonary shunts or (bidirectional) total cavo-
pulmonary shunts. A 6- to 7-mm AVF probably will haveThe Journal of Thoracic and Caa finite maximal flow. Superior performance of AVF with
a unidirectional cavopulmonary shunt may be due to con-
centrating flow to a limited volume of lung tissue. Doubling
the downstream lung volume probably dilutes the beneficial
effects on cavopulmonary shunt flow.
This analysis examined the outcomes of death with a func-
tioning AVF in situ and AVF occlusion as separate out-
comes, rather than treating them as a composite end point.
However, both outcomes represent a conceptual clinical
‘‘failure’’ of the AVF. If the composite outcome (of either
death or AVF occlusion) is considered, univariate predictors
of early composite failure remain: (1) pulmonary arteriove-
nous malformations (P ¼ .04), (2) previous bidirectional
cavopulmonary shunt (P< .01), and (3) AVF after comple-
tion Fontan (P ¼ .05).rdiovascular Surgery c Volume 139, Number 1 133
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tion for contemporary practice is the age at which AVFs
were received. Both in this and previous1,2,15 reports, most
patients receiving an AVF were young teenagers. It remains
to be clarified whether AVF offers comparable performance
in young infants with failing cavopulmonary shunts.CONCLUSIONS
We reviewed this unique experience to determine the du-
rability of a palliative low-risk option for advanced cyanotic
disease. We are not promoting AVF in the current era. How-
ever, we suspect that creating an AVF is either an unknown
or forgotten option in contemporary practice for patients
with severe cyanotic disease. Severe cyanosis from any
cause is disabling. It causes severe fatigue and headaches,
and may lead to intracerebral thrombosis or hemorrhage.
The presence of well-known risk factors may render Fontan
completion an unattractive strategy with excessive morbid-
ity and shortened longevity. Some patients, especially
adults, and their families may not be willing to accept these
outcomes with a high-risk Fontan procedure. Although
cardiac transplantation is a theoretic option, in practice these
patients are in competition with patients with acute coronary
disease and seldom achieve the priority necessary to actually
receive a transplant. In either case, an AVF is low risk (po-
tentially an outpatient procedure) and provides relief from
the effects of severe cyanosis. Our experience indicates
that use of an AVF as a bridge to further management should
remain an option in the decision management of the rare pa-
tient with intractable cyanosis for whom Fontan completion
and transplantation are unappealing.References
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FIGURE E1. Histogram illustrating the number of patients receiving an
AVF in each 5-year period from 1975. The date pertains to the date at which
the AVF was created.
TABLE E1. Clinical history leading to decision to pursue systemic
arteriovenous fistula to manage cyanosis
History leading to AVF
1 Previous Pott’s shunt with pulmonary hypertension
2 Hypoplastic left PA; judged not candidate for Fontan
3 Pre-Fontan; Glenn and Pott’s shunts with gradual cyanosis
4 Pre-Fontan; Glenn and Pott’s shunts with gradual cyanosis
5 Pre-Fontan; Glenn and Pott’s shunts with gradual cyanosis
6 LPA stenosis after Pott’s shunt; Fontan failed.
7 Previous repair of nonconfluent PAs; Fontan failed.
8 Branch PA stenoses with stents; LPA hypoplasia
9 Interstitial restrictive lung disease; numerous large venous
thromboses
10 Poor cavopulmonary shunt flow secondary to innominate vein
thrombosis
11 Gradual cyanosis with elevated LV end-diastolic pressures; not
Fontan candidate
12 Branch PA stenoses; not Fontan candidate
13 Poor LV function; not Fontan candidate
14 Poor LV function; not Fontan candidate
15 Poor LV function; not Fontan candidate
16 Pulmonary arteriovenous malformations
17 Pulmonary arteriovenous malformations
18 Pulmonary arteriovenous malformations
19 Pulmonary arteriovenous malformations
20 Pulmonary arteriovenous malformations
21 Pulmonary arteriovenous malformations
AVF,Arteriovenous fistula; PA, pulmonary artery; LPA, left pulmonary artery; LV, left
ventricular. Six patients had pulmonary arteriovenous malformations confirmed by
cardiac catheterization. The remaining 15 patients had no evidence of pulmonary ar-
teriovenous malformations on cardiac catheterization.
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